ChemDiv and SK Corporation Extend Collaboration into 2008
News Feb 15, 2006
Under this agreement, ChemDiv is supplying SK Corporation with discovery chemistry libraries and medicinal chemistry services in addition to assisting the company in hit-to-lead optimization projects initiated at SK Institute of Technology in Daejeon.
"We are very proud that SK Corporation, Korea's leading integrated energy and chemical company and a pioneer in new drug development business, maintains ChemDiv as the partner for their new drug discovery research projects," said Nikolay Savchuk, President of ChemDiv.
"This collaboration is an indicator of continued confidence in the value ChemDiv brings as a partner to the SK Corporation Drug Discovery Program."
"We look forward to our continued collaboration with ChemDiv," said Dr. Byongsung Kwak, Head of BioPharmaceutical Division of SK Corporation.
"We are confident that the company's diverse sets of drug-like small molecules and their state-of-the-art facilities and capabilities in both the US and Europe will continue to be a significant asset to SK Corporation in our research, development, manufacturing and marketing of drugs, active substances and intermediates."
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE